RAPT Therapeutics, Inc.

NASDAQ:RAPT

3.1 (USD) • At close November 7, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q1
Revenue 005.2880000.64100.8860.6410.7560.9660.8691.2221.3021.5281.2770.93500000000
Cost of Revenue 0.3050.3140.3230.9080.8530.8830.730.7280.70.6890.231000000000000000
Gross Profit -0.305-0.3144.965-0.908-0.853-0.883-0.089-0.7280.186-0.0480.5250.9660.8691.2221.3021.5281.2770.93500000000
Gross Profit Ratio 000.939000-0.13900.21-0.0750.694111111100000000
Reseach & Development Expenses 22.6424.78126.76427.02221.64225.57419.45416.59914.35916.6714.29915.72513.1913.77110.90412.91210.98610.68310.198.5828.2677.878.389.1816.97.306
General & Administrative Expenses 6.697.7376.4536.8976.7225.9884.9775.0795.4364.7484.4913.7743.764.0123.4833.1972.8023.2892.6251.7332.6921.6741.2911.3641.4681.057
Selling & Marketing Expenses -0.305-0.314-0.32300000000000000000000000
SG&A 6.3857.4236.136.8976.7225.9884.9775.0795.4364.7484.4913.7743.764.0123.4833.1972.8023.2892.6251.7332.6921.6741.2911.3641.4681.057
Other Expenses 1.6671.9972.3412.5483.0842.2911.480.443-0.2750.3090.105-0.118-0.0290.0470.5490.2370.3910.1350.2590.3440.3330.3560.2410.2610.1640.132
Operating Expenses 29.02532.20432.89433.91928.36431.56224.43121.67819.79521.41818.7919.49916.9517.78314.38716.10913.78813.97212.81510.31510.9599.5449.67110.5458.3688.363
Operating Income -29.33-32.518-33.217-33.919-28.364-31.562-24.431-21.678-18.909-20.777-18.034-18.533-16.081-16.561-13.085-14.581-12.511-13.037-12.815-10.315-10.959-9.544-9.671-10.545-8.368-8.363
Operating Income Ratio 00-6.282000-38.1140-21.342-32.413-23.854-19.185-18.505-13.552-10.05-9.543-9.797-13.94300000000
Total Other Income Expenses Net 1.6671.9972.3412.5483.0842.2911.480.443-0.2750.3090.105-0.118-0.0290.0470.5490.2370.3910.1350.2590.3440.3330.3560.2410.2610.1640.132
Income Before Tax -27.663-30.521-30.876-31.371-25.28-29.271-22.951-21.235-19.184-20.468-17.929-18.651-16.11-16.514-12.536-14.344-12.12-12.902-12.556-9.971-10.626-9.188-9.43-10.284-8.204-8.231
Income Before Tax Ratio 00-5.839000-35.8050-21.652-31.931-23.716-19.307-18.539-13.514-9.628-9.387-9.491-13.79900000000
Income Tax Expense 00.2712.885-0.325-0.269-2.291-1.48-0.4430.275-0.309-0.2310.0290.05600.1990.2870.2670.2370.660000000
Net Income -27.663-30.521-30.876-31.371-25.28-26.98-21.471-20.792-19.459-20.159-17.929-18.651-16.11-16.514-12.735-14.631-12.387-13.139-13.216-9.971-10.626-9.188-9.43-10.284-8.204-8.231
Net Income Ratio 00-5.839000-33.4960-21.963-31.449-23.716-19.307-18.539-13.514-9.781-9.575-9.7-14.05200000000
EPS -0.71-0.79-0.8-0.82-0.66-0.7-0.6-0.62-0.62-0.68-0.61-0.63-0.63-0.66-0.52-0.6-0.51-0.56-0.87-12.41-0.47-0.53-0.54-0.59-0.48-0.48
EPS Diluted -0.71-0.79-0.8-0.82-0.66-0.7-0.6-0.62-0.62-0.68-0.61-0.63-0.63-0.66-0.52-0.6-0.51-0.56-0.87-12.41-0.47-0.53-0.54-0.59-0.48-0.48
EBITDA -29.025-32.204-32.894-33.919-28.364-31.263-24.431-21.418-18.635-20.516-18.034-18.304-15.825-16.281-13.085-14.318-12.511-12.838-12.815-9.973-10.621-9.213-9.377-10.236-8.046-8.051
EBITDA Ratio 00-6.22000-38.1140-21.033-32.006-23.854-18.948-18.211-13.323-10.05-9.37-9.797-13.7300000000